Binding mechanism of the molecular glue inhibitor in overcoming the “undruggable” Kirsten rat sarcoma viral oncogene homolog through conformational remodeling
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy · 2027-02 · 366 · 128897
DOI: 10.1016/j.saa.2026.128897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2027-02. Verfasst von Houde Liang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Physics and Optoelectronics, Shandong Normal University, Jinan 250358, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Cyclophilin A. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kirsten rat sarcoma viral oncogene homolog (KRAS) protein, a member of prevalent oncogenic driver, is difficult to be targeted and inhibited by traditional inhibitors due to its complex binding surface and mutation-prone property. Molecular glue inhibitor RMC-7977 is designed to break through the undruggable property of KRAS, it bridges KRAS and cyclophilin A (CYPA) to inhibit KRAS. However, RMC-7977's molecular mechanism underlying inhibitory effect and conformational remodeling as a molecular glue are still unclear. To address these research gaps, molecular dynamics simulations were employed to investigate the interaction and conformational mechanisms among KRAS, RMC-7977, and CYPA. The calculated binding free energies are consistent with the experimentally determined ranking. Conformational analysis suggests RMC-7977 fill the void as a molecular glue to change the CYPA's conformation and hydrophobic interaction to bridge between KRAS and CYPA. Comparative studies of mutants reveal that RMC-7977's binding site is far from GLY12, rendering it unaffected by these mutations and conferring with pan-inhibitor potential. This study provides important insights for RMC-7977 to optimize KRAS-CYPA interaction and molecular glue function at the molecular level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Physics and Optoelectronics, Shandong Normal University, Jinan 250358, China.
- School of Physics and Optoelectronics, Shandong Normal University, Jinan 250358, China. Electronic address: liuxinguo@sdnu.edu.cn.
- School of Information Engineering, Qingdao Binhai University, Qingdao 266555, China. Electronic address: luosong@qdbhu.edu.cn.
- School of Physics and Optoelectronics, Shandong Normal University, Jinan 250358, China. Electronic address: duanll@sdnu.edu.cn.
Förderung
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
Zitieren
APA
Liang, H., Xu, X., Zhang, E., Liu, J., Wang, Y., Liu, X., Luo, S., & Duan, L. (2027). Binding mechanism of the molecular glue inhibitor in overcoming the “undruggable” Kirsten rat sarcoma viral oncogene homolog through conformational remodeling. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 366, 128897. https://doi.org/10.1016/j.saa.2026.128897
Vancouver
Liang H, Xu X, Zhang E, Liu J, Wang Y, Liu X, et al. Binding mechanism of the molecular glue inhibitor in overcoming the “undruggable” Kirsten rat sarcoma viral oncogene homolog through conformational remodeling. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2027;366:128897. doi:10.1016/j.saa.2026.128897
BibTeX
@article{Liang2027,
author = {Liang, Houde and Xu, Xiaole and Zhang, Enhao and Liu, Jinxin and Wang, Yihan and Liu, Xinguo and Luo, Song and Duan, Lili},
title = {Binding mechanism of the molecular glue inhibitor in overcoming the “undruggable” Kirsten rat sarcoma viral oncogene homolog through conformational remodeling},
journal = {Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy},
year = {2027},
volume = {366},
pages = {128897},
doi = {10.1016/j.saa.2026.128897}
}
EUVIMED